Syngene marks a significant Q1 performance in 2023.
Syngene International Limited is making its mark in the healthcare sector, registering a remarkable Q1 performance with a 26% YoY increase in both revenues and profit after tax. The impressive financial standing is powering the company’s growth and expansion strategies.
Syngene made a notable stride by acquiring a biologics manufacturing facility from Stelis Biopharma Ltd. This acquisition enhances Syngene’s capabilities, bringing in an additional 20,000 liters of biologics capacity, and fortifying its standing as a leading contract development and manufacturing service provider.
In addition to the expansion in biologics, Syngene secured US FDA approval for its API manufacturing facility in Mangalore. This certification speaks volumes about the company’s unwavering commitment to quality standards.
Committed to long-term growth, Syngene has acquired additional land in Hyderabad. This step underpins the company’s focus on enhancing its Research Services division, showcasing its future-forward approach.
